EP3256471B1 - Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection - Google Patents

Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection Download PDF

Info

Publication number
EP3256471B1
EP3256471B1 EP16703311.7A EP16703311A EP3256471B1 EP 3256471 B1 EP3256471 B1 EP 3256471B1 EP 16703311 A EP16703311 A EP 16703311A EP 3256471 B1 EP3256471 B1 EP 3256471B1
Authority
EP
European Patent Office
Prior art keywords
methoxy
oxo
quinolizine
thienyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16703311.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3256471A1 (en
Inventor
Xingchun Han
Min Jiang
Song Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP3256471A1 publication Critical patent/EP3256471A1/en
Application granted granted Critical
Publication of EP3256471B1 publication Critical patent/EP3256471B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Definitions

  • the present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to HBsAg (HBV Surface antigen) inhibitors and HBV DNA production inhibitors useful for treating HBV infection.
  • HBsAg HBV Surface antigen
  • the present invention relates to novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives having pharmaceutical activity, their manufacture, pharmaceutical compositions containing them and their potential use as medicaments.
  • the present invention relates to compounds of formula I wherein R 1 to R 5 and Ar are as described below, or to pharmaceutically acceptable salts, or to enantiomers thereof.
  • the hepatitis B virus is an enveloped, partially double-stranded DNA virus.
  • the compact 3.2 kb HBV genome consists of four overlapping open reading frames (ORF), which encode for the core, polymerase (Pol), envelope and X-proteins.
  • ORF open reading frames
  • the Pol ORF is the longest and the envelope ORF is located within it, while the X and core ORFs overlap with the Pol ORF.
  • the lifecycle of HBV has two main events: 1) generation of closed circular DNA (cccDNA) from relaxed circular (RC DNA), and 2) reverse transcription of pregenomic RNA (pgRNA) to produce RC DNA. Prior to the infection of host cells, the HBV genome exists within the virion as RC DNA.
  • HBV virions are able to gain entry into host cells by non-specifically binding to the negatively charged proteoglycans present on the surface of human hepatocytes ( Schulze, A., P. Gripon & S. Urban. Hepatology, 46, (2007), 1759-68 ) and via the specific binding of HBV surface antigens (HBsAg) to the hepatocyte sodium-taurocholate cotransporting polypeptide (NTCP) receptor ( Yan, H. et al. J Virol, 87, (2013), 7977-91 ).
  • HBV surface antigens HBV surface antigens
  • NTCP sodium-taurocholate cotransporting polypeptide
  • cccDNA acts as the template for all viral mRNAs and as such, is responsible for HBV persistence in infected individuals.
  • the transcripts produced from cccDNA are grouped into two categories; Pregenomic RNA (pgRNA) and subgenomic RNA.
  • IFN- ⁇ was shown to inhibit HBV replication and viral HBsAg production by decreasing the transcription of pgRNA and subgenomic RNA from the HBV covalently closed circular DNA (cccDNA) minichromosome.
  • cccDNA covalently closed circular DNA
  • nascent pgRNA is packaged with viral Pol so that reverse transcription of pgRNA, via a single stranded DNA intermediate, into RC DNA can commence.
  • the mature nucleocapsids containing RC DNA are enveloped with cellular lipids and viral L, M, and S proteins and then the infectious HBV particles are then released by budding at the intracellular membrane ( Locarnini, S. Semin Liver Dis, (2005), 25 Suppl 1, 9-19 ).
  • non-infectious particles are also produced that greatly outnumber the infectious virions.
  • These empty, enveloped particles (L, M and S) are referred to as subviral particles.
  • subviral particles share the same envelope proteins and as infectious particles, it has been surmised that they act as decoys to the host immune system and have been used for HBV vaccines.
  • the S, M, and L envelope proteins are expressed from a single ORF that contains three different start codons. All three proteins share a 226aa sequence, the S-domain, at their C-termini. M and L have additional pre-S domains, Pre-S2 and Pre-S2 and Pre-S1, respectively. However, it is the S-domain that has the HBsAg epitope ( Lambert, C. & R. Prange. Virol J, (2007), 4, 45 ).
  • HBV Hepatitis B virus
  • the secretion of antiviral cytokines in response to HBV infection by the hepatocytes and/or the intra-hepatic immune cells plays a central role in the viral clearance of infected liver.
  • chronically infected patients only display a weak immune response due to various escape strategies adopted by the virus to counteract the host cell recognition systems and the subsequent antiviral responses.
  • HBV empty subviral particles SVPs, HBsAg
  • CHB chronically infected patients
  • HBsAg has been reported to suppress the function of immune cells such as monocytes, dendritic cells (DCs) and natural killer (NK) cells by direct interaction ( Op den Brouw et al. Immunology, (2009b), 126, 280-9 ; Woltman et al. PLoS One, (2011), 6, e15324 ; Shi et al. J Viral Hepat. (2012), 19, e26-33 ; Kondo et al. ISRN Gasteroenterology, (2013), Article ID 935295 ).
  • DCs dendritic cells
  • NK natural killer
  • HBsAg quantification is a significant biomarker for prognosis and treatment response in chronic hepatitis B.
  • Current therapy such as Nucleos(t)ide analogues are molecules that inhibit HBV DNA synthesis but are not directed at reducing HBsAg level.
  • Nucleos(t)ide analogs even with prolonged therapy, have demonstrated rates of HBsAg clearance comparable to those observed naturally (between -1%-2%) ( Janssen et al. Lancet, (2005), 365, 123-9 ; Marcellin et al. N. Engl. J.
  • the present invention relates to compounds of formula I wherein
  • C 1-6 alkyl alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1-butyl, 2-butyl, tert -butyl and the like.
  • Particular "C 1-6 alkyl” groups are methyl, ethyl, isopropyl and tert-butyl.
  • C 3-7 cycloalkyl refers to a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • Particular "C 3-7 cycloalkyl” groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C 1-6 alkoxy alone or in combination signifies a group C 1-6 alkyl-O-, wherein the "C 1-6 alkyl” is as defined above; examples for C 1-6 alkoxy are methoxy, ethoxy, propoxy, iso- propoxy, n -butoxy, iso -butoxy, 2-butoxy, tert -butoxy and the like.
  • Particular "C 1-6 alkoxy” groups are methoxy and ethoxy and more particularly methoxy.
  • halogen means fluorine, chlorine, bromine or iodine.
  • haloC 1-6 alkyl denotes a C 1-6 alkyl group wherein at least one of the hydrogen atoms of the C 1-6 alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms.
  • haloC 1-6 alkyl include monofluoro-, difluoro- or trifluoro-methyl, - ethyl or -propyl, for example 3,3,3-trifluoropropyl, 3,3- difluoropropyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, difluoromethyl or trifluoromethyl.
  • Particular "haloC 1-6 alkyl” group is difluoromethyl or trifluoromethyl.
  • monocyclic heterocycloalkyl is a monovalent saturated or partly unsaturated monocyclic ring system of 4 to 7 ring atoms, comprising 1, 2, or 3 ring heteroatoms selected from N, O and S, the remaining ring atoms being carbon.
  • Examples for monocyclic heterocycloalkyl are aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, tetrahydrofuranyl, tetrahydro-thienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl.
  • Particular "monocyclic heterocycloalkyl” groups are piperidinyl, morpholinyl, 2-ox
  • N -containing monocyclic heterocycloalkyl is a "monocyclic heterocycloalkyl" as defined above wherein at least one of the heteroatoms is N.
  • Examples for " N -containing monocyclic heterocycloalkyl” are aziridinyl, azetidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, or oxazepanyl.
  • Particular " N -containing monocyclic heterocycloalkyl” groups are piperidinyl, morpholinyl, 2-oxo-pyr
  • amino denotes a group of the formula -NR'R" wherein R' and R" are independently hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 3-7 cycloalkyl, heteroC 3-7 cycloalkyl, aryl or heteroaryl. Alternatively, R' and R", together with the nitrogen to which they are attached, can form a heteroC 3-7 cycloalkyl.
  • carbonyl alone or in combination refers to the group -C(O)-.
  • cyano alone or in combination refers to the group -CN.
  • C 1-6 alkylsulfanyl denotes the group -S-R', wherein R' is a C 1-6 alkyl group as defined above.
  • C 1-6 alkylsulfonyl denotes a group -SO 2 -R', wherein R' is a C 1-6 alkyl group as defined above.
  • Examples of C 1-6 alkylsulfonyl include methylsulfonyl and ethylsulfonyl.
  • enantiomer denotes two stereoisomers of a compound which are non-superimposable mirror images of one another.
  • diastereomer denotes a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities.
  • the compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases.
  • Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p -toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like.
  • Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide.
  • the chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. It is for example described in Bastin R.J., et al., Organic Process Research & Development 2000, 4, 427-435 ; or in Ansel, H., et al., In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457 . Particular are the sodium salts of the compounds of formula I.
  • Racemates can be separated according to known methods into the enantiomers.
  • diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid.
  • the present invention provides (i) novel compounds having the general formula I: wherein
  • Another embodiment of present invention is (iii) a compound of formula I as defined above, or pharmaceutically acceptable salts, or enantiomers thereof, wherein R 1 is hydrogen, R 4 is hydrogen, R 5 is hydrogen, and all remaining substituents have the significances given herein before.
  • Another embodiment of present invention is (iv) a compound of formula I as defined above, or pharmaceutically acceptable salts, or enantiomers thereof, wherein R 2 is C 1-6 alkoxy, and all remaining substituents have the significances given herein before.
  • a further embodiment of present invention is (v) a compound of formula I as defined above, or pharmaceutically acceptable salts, or enantiomers thereof, wherein R is methoxy, and all remaining substituents have the significances given herein before.
  • Another embodiment of present invention is (vi) a compound of formula I as defined above, or pharmaceutically acceptable salts, or enantiomers thereof, wherein R 3 is pyrrolidinyl or OR 6 , wherein R 6 is C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkylC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, carboxyC 1-6 alkyl, C 1-6 alkylsulfanylC 1-6 alkyl, cyanoC 1-6 alkyl, aminoC 1-6 alkyl, C 1-6 alkylcarbonylaminoC 1-6 alkyl, C 1-6 alkylsulfonylaminoC 1-6 alkyl or C 1-6 alkoxycarbonylaminoC 1-6 alkyl, and all remaining substituents have the significances given herein before.
  • FIG. 1 Further embodiment of present invention is (vii) a compound of formula I as defined above, or pharmaceutically acceptable salts, or enantiomers thereof, wherein R 3 is OR 6 , wherein R 6 is methyl, isobutyl, trifluoroethyl, cyclopropylmethyl, cyanopropyl, hydroxypropyl, hydroxyhexyl, hydroxydimethylpropyl, methoxypropyl, carboxypropyl, methylsulfanylpropyl, aminohexyl, methylcarbonylaminohexyl, methylsulfonylaminohexyl or methoxycarbonylaminohexyl, and all remaining substituents have the significances given herein before.
  • Another embodiment of present invention is (viii) a compound of formula I as defined above, or pharmaceutically acceptable salts, or enantiomers thereof, wherein Ar is phenyl, phenyl substituted by C 1-6 alkyl or halogen, thienyl or thienyl substituted by C 1-6 alkyl, and all remaining substituents have the significances given herein before.
  • FIG. 1 Further embodiment of present invention is (ix) a compound of formula I as defined above, or pharmaceutically acceptable salts, or enantiomers thereof, wherein Ar is phenyl; phenyl substituted by methyl, fluoro or chloro; thienyl or thienyl substituted by methyl, and all remaining substituents have the significances given herein before.
  • a further embodiment of present invention is (x) a compound of formula I, wherein
  • the compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R 1 to R 5 and Ar are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.
  • R 7 is C 1-6 alkyl
  • the compound of formula I can be prepared according to Scheme 1. Coupling reaction of bromo-benzene II with ketone III affords Compound IV.
  • the reaction can be carried out in the presence of a Pd catalyst such as Pd 2 (dba) 3 , Pd(PPh 3 ) 4 or PdCl 2 (PPh 3 ) 2 , a ligand such as Xantphos, and a suitable base such as t -BuONa, Na 2 CO 3 or CS 2 CO 3 , in a suitable solvent such as THF, toluene or 1,4-dioxane at a temperature between room temperature and 130°C.
  • a Pd catalyst such as Pd 2 (dba) 3 , Pd(PPh 3 ) 4 or PdCl 2 (PPh 3 ) 2
  • a ligand such as Xantphos
  • a suitable base such as t -BuONa, Na 2 CO 3 or CS 2 CO 3
  • Compound V is heated with ethyl formate or formic acid in a solvent such as ethanol or dioxane to afford Compound XI.
  • Compound XI is treated with POCl 3 in a suitable solvent such as acetonitrile or DCM at a temperature between room temperature and 100°C to give Compound XII.
  • Compound XII reacts with C 1-6 alkyl 2-(ethoxymethylene)-3-oxo-butanoate in a solvent such as ethanol to give Compound XIII.
  • Compound XIV is obtained by dehydrogenation of compound XIII by using p- chloranil. Hydrolyzation of Compound XIV with a base such as lithium hydroxide or sodium hydroxide in a suitable solvent such as THF/H 2 O, EtOH/H 2 O or MeOH/H 2 O affords the compound of formula I.
  • This invention also relates to a process for the preparation of a compound of formula I comprising
  • a compound of formula I when manufactured according to the above process is also an object of the invention.
  • the invention also relates to a compound of formula I for use as therapeutically active substance.
  • compositions are formulated, dosed, and administered in a fashion consistent with good medical practice.
  • Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • the "effective amount" of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to inhibit HBsAg. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.
  • the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg/kg, alternatively about 0.01 to 100 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day.
  • oral unit dosage forms such as tablets and capsules, preferably contain from about 0.1 to about 1000 mg of the compound of the invention.
  • the compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc.
  • Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.
  • a typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient.
  • Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004 ; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000 ; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005 .
  • the formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).
  • buffers stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing
  • An example of a suitable oral dosage form is a tablet containing about 0.1 to 1000 mg of the compound of the invention compounded with about 0 to 2000 mg anhydrous lactose, about 0 to 2000 mg sodium croscarmellose, about 0 to 2000 mg polyvinylpyrrolidone (PVP) K30, and about 0 to 2000 mg magnesium stearate.
  • the powdered ingredients are first mixed together and then mixed with a solution of the PVP.
  • the resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment.
  • An example of an aerosol formulation can be prepared by dissolving the compound, for example 0.1 to 1000 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired.
  • the solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.
  • An embodiment therefore, includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.
  • a compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition: Per tablet Active ingredient 200 mg Microcrystalline cellulose 155 mg Corn starch 25 mg Talc 25 mg Hydroxypropylmethylcellulose 20 mg 425 mg
  • a compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition: Per capsule Active ingredient 100.0 mg Corn starch 20.0 mg Lactose 95.0 mg Talc 4.5 mg Magnesium stearate 0.5 mg 220.0 mg
  • the compounds of the invention can inhibit HBsAg production or secretion and inhibit HBV gene expression. Accordingly, the compounds of the invention are useful for the treatment or prophylaxis of HBV infection.
  • the invention relates in particular to the use of a compound of formula I for the preparation of a medicament for the treatment or prophylaxis of HBV infection.
  • Also disclosed is a method for the treatment or prophylaxis of HBV infection which method comprises administering an effective amount of a compound of Formula I, a stereoisomer, tautomer, prodrug, conjugates or pharmaceutically acceptable salt thereof.
  • the compounds of the invention can be combined with other anti HBV agents such as interferon alpha-2b, interferon alpha-2a, and interferon alphacon-1 (pegylated and unpegylated), ribavirin, lamivudine (3TC), entecavir, tenofovir, telbivudine (LdT), adefovir, or other emerging anti HBV agents such as HBV RNA replication inhibitor, HBsAg secretion inhibitors, HBV capsid inhibitors, antisense oligomer, siRNA, HBV therapeutic vaccine, HBV prophylactic vaccine, HBV antibody therapy (monoclonal or polyclonal) and TLR 2, 3, 7, 8 and 9 agonists for the treatment or prophylaxis of HBV.
  • anti HBV agents such as interferon alpha-2b, interferon alpha-2a, and interferon alphacon-1 (pegylated and unpegylated), ribavirin, lam
  • the microwave assisted reactions were carried out in a Biotage Initiator Sixty or CEM Discover.
  • Step 4 Preparation of N -[2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-phenyl-ethyl]formamide
  • Step 6 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-phenyl-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-phenyl-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 8 Preparation of 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-phenyl-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of 2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-(3-thienyl)ethanone
  • Step 3 Preparation of N -[2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-(3-thienyl)ethyl]formamide
  • Step 5 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-(3-thienyl)-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 6 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-(3-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-(3-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of 2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-(2-thienyl)ethanone
  • Step 3 Preparation of N -[2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-(2-thienyl)ethyl]formamide
  • N -[2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-(2-thienyl)ethyl]formamide 750 mg, 2.15 mmol
  • POCl 3 493 mg, 3.22 mmol
  • the mixture was heated and stirred at 40 °C for 2 hrs, and then poured into ammonia water.
  • the resulting mixture was extracted with DCM.
  • the organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure.
  • the residue was purified by column chromatography to give 7-methoxy-6-(3-methoxypropoxy)-3-(2-thienyl)-3,4-dihydroisoquinoline (400 mg) as a gray solid.
  • Step 5 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-(2-thienyl)-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 6 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of 10-methoxy-9-(3-methoxypropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of 1-(4-benzyloxyphenyl)-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethanone
  • Step 3 Preparation of N -[1-(4-benzyloxyphenyl)-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethyl]formamide
  • Step 5 Preparation of ethyl 6-(4-benzyloxyphenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of ethyl 6-(4-hydroxyphenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 8 Preparation of 6-(4-hydroxyphenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 10-methoxy-6-(4-methoxyphenyl)-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 10-methoxy-6-(4-methoxyphenyl)-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Example 7 10-methoxy-9-(3-methoxypropoxy)-6-(4-methyl-2-thienyl)-2-oxo-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of 2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-(4-methyl-2-thienyl)ethanone
  • Step 3 Preparation of N -[2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-(4-methyl-2-thienyl)ethyl]formamide
  • Step 4 Preparation of 7-methoxy-6-(3-methoxypropoxy)-3-(4-methyl-2-thienyl)-3,4-dihydroisoquinoline
  • Step 5 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-6-(4-methyl-2-thienyl)-2-oxo-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 6 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-6-(4-methyl-2-thienyl)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of 10-methoxy-9-(3-methoxypropoxy)-6-(4-methyl-2-thienyl)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • the filter cake was purified by prep-HPLC to give 10-methoxy-9-(3-methoxypropoxy)-6-(4-methyl-2-thienyl)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid (64 mg) as a white solid.
  • Step 1 Preparation of 1-(3-chlorophenyl)-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethanone
  • Step 3 Preparation of N -[1-(3-chlorophenyl)-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethyl]formamide
  • Step 5 Preparation of ethyl 6-(3-chlorophenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 6 Preparation of ethyl 6-(3-chlorophenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of 6-(3-chlorophenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of 1-(4-fluorophenyl)-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethanone
  • Step 3 Preparation of N -[1-(4-fluorophenyl)-2-[4-methoxy-3-(3-methoxypropoxy)phenyl]ethyl]formamide
  • Step 5 Preparation of ethyl 6-(4-fluorophenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 6 Preparation of ethyl 6-(4-fluorophenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of 6-(4-fluorophenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • the filter cake was purified by prep-HPLC to give 6-(4-fluorophenyl)-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid (22 mg) as a white solid.
  • Step 1 Preparation of 2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-( o- tolyl)ethanone
  • Step 3 Preparation of N -[2-[4-methoxy-3-(3-methoxypropoxy)phenyl]-1-( o- tolyl)ethyl]formamide
  • Step 4 Preparation of 7-methoxy-6-(3-methoxypropoxy)-3-( o -tolyl)-3,4-dihydroisoquinoline
  • Step 5 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-6-(o-tolyl)-2-oxo-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 6 Preparation of ethyl 10-methoxy-9-(3-methoxypropoxy)-6-( o -tolyl)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of 10-methoxy-9-(3-methoxypropoxy)-6-( o -tolyl)-2-oxo-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 6 Preparation of ethyl 9-methoxy-8-methyl-2-oxo-6-(2-thienyl)-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of ethyl 9-methoxy-8-methyl-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 8 Preparation of 9-methoxy-8-methyl-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 4 Preparation of N -[2-(3-benzyloxy-4-methoxy-phenyl)-1-(2-thienyl)ethyl]formamide
  • Step 6 Preparation of ethyl 9-benzyloxy-10-methoxy-2-oxo-6-(2-thienyl)-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 8 Preparation of 9-benzyloxy-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-hydroxy-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of ethyl 9,10-dimethoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 3 Preparation of 9,10-dimethoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-isobutoxy-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-isobutoxy-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-(cyclopropylmethoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-(cyclopropylmethoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 2 Preparation of ethyl 10-methoxy-2-oxo-9-(3-pyrazol-l-ylpropoxy)-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 3 Preparation of 10-methoxy-2-oxo-9-(3-pyrazol-1-ylpropoxy)-6-(2-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-(3-hydroxypropoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-(3-hydroxypropoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-(3-bromopropoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of ethyl 10-methoxy-2-oxo-9-[3-(1-piperidyl)propoxy]-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 3 Preparation of 10-methoxy-2-oxo-9-[3-(1-piperidyl)propoxy]-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid formate
  • Step 2 Preparation of 9-(3-cyanopropoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-(2-bromoethoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 10-methoxy-2-oxo-9-[2-(2-oxopyrrolidin-1-yl)ethoxy]-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-[6-( tert -butoxycarbonylamino)hexoxy]-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-[6-( tert -butoxycarbonylamino)hexoxy]-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-(6-aminohexoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate hydrochloride
  • Step 2 Preparation of 9-(6-aminohexoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid formate
  • Step 1 Preparation of ethyl 9-(6-acetamidohexoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-(6-acetamidohexoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-[6-(methanesulfonamido)hexoxy]-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-[6-(methanesulfonamido)hexoxy]-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-(6-hydroxyhexoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-(6-hydroxyhexoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-(3-hydroxy-2,2-dimethyl-propoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-(3-hydroxy-2,2-dimethyl-propoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 10-methoxy-2-oxo-6-(2-thienyl)-9-(2,2,2-trifluoroethoxy)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 10-methoxy-2-oxo-6-(2-thienyl)-9-(2,2,2-trifluoroethoxy)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 10-methoxy-9-(3-morpholinopropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 10-methoxy-9-(3-morpholinopropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • the filter cake was purified by prep-HPLC to afford 10-methoxy-9-(3-morpholinopropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate (7 mg) as a white solid.
  • Step 2 Preparation of ethyl 10-methoxy-2-oxo-6-(2-thienyl)-9-[3-(1,2,4-triazol-1-yl)propoxy]-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 3 Preparation of 10-methoxy-2-oxo-6-(2-thienyl)-9-[3-(1,2,4-triazol-1-yl)propoxy]-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 9-(4-ethoxy-4-oxo-butoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-(3-carboxypropoxy)-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 2 Preparation of ethyl 10-methoxy-9-(3-methylsulfanylpropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 3 Preparation of 10-methoxy-9-(3-methylsulfanylpropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 2 Preparation of ethyl 10-methoxy-9-(3-methylsulfonylpropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 3 Preparation of 10-methoxy-9-(3-methylsulfonylpropoxy)-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • Step 2 Preparation of ethyl 10-methoxy-9-methyl-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 1 Preparation of ethyl 9-ethyl-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 9-ethyl-10-methoxy-2-oxo-6-(2-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 10-methoxy-2-oxo-9-propyl-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 10-methoxy-2-oxo-9-propyl-6-(2-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 1 Preparation of ethyl 10-methoxy-2-oxo-9-pyrrolidin-1-yl-6-(2-thienyl)-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 2 Preparation of 10-methoxy-2-oxo-9-pyrrolidin-1-yl-6-(2-thienyl)-6,7-dihydrobenzo[a] quinolizine-3-carboxylic acid
  • Step 6 Preparation of ethyl 6-(benzothiophen-2-yl)-10-chloro-9-(3-methoxypropoxy)-2-oxo-1,6,7,11b-tetrahydrobenzo[a]quinolizine-3-carboxylate
  • Step 7 Preparation of ethyl 6-(benzothiophen-2-yl)-10-chloro-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylate
  • Step 8 Preparation of 6-(benzothiophen-2-yl)-10-chloro-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
  • HepG2.2.15 cells ( Acs et al. Proc Natl Acad Sci U S A, 84, (1987), 4641-4 ), a constitutively HBV-expressing cell line were cultured in DMEM+Glutamax-I medium (Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (Invitrogen) and G418 (Invitrogen) at a final concentration of 200 mg/L and maintained in 5% CO 2 at 37°C.
  • DMEM+Glutamax-I medium Invitrogen, Carlsbad, CA, USA
  • 10% fetal bovine serum Invitrogen
  • G418 Invitrogen
  • HepG2.2.15 cells were seeded in duplicate into white, 96-well plates at 1.5 x 10 4 cells/well. The cells were treated with a three-fold serial dilution series of the compounds in DMSO. The final DMSO concentration in all wells was 1% and DMSO was used as no drug control.
  • the HBsAg chemiluminescence immunoassay (CLIA) kit (Autobio Diagnostics Co., Zhengzhou, China, Catalog number: CL0310-2) was used to measure the levels of secreted HBV antigens semi-quantitatively.
  • CLIA HBsAg chemiluminescence immunoassay
  • 50 ⁇ L/well culture supernatant was used and HBsAg was quantified using HBsAg chemiluminescence immunoassay (CLIA) kit (Autobio Diagnostics Co., Zhengzhou, China, Catalog number: CL0310-2), 50 ⁇ L of the supernatant was transferred to the CLIA assay plate and 50 ⁇ L of enzyme conjugate reagent was added into each well. The plates were sealed and gently agitated for 1 hour at room temperature.
  • the supernatant-enzyme-mixture was discarded and wells were washed 6 times with 300 ⁇ L of PBS.
  • the residual liquid was removed by plating the CLIA plate right side down on absorbent tissue paper. 25 ⁇ L of substrates A and B were added to each well.
  • Luminance was measured using a luminometer (Mithras LB 940 Multimode Microplate Reader) after 10 minutes incubation. Dose-response curves were generated and the IC 50 value was extrapolated by using the E-WorkBook Suite (ID Business Solutions Ltd., Guildford, UK).
  • the IC 50 was defined as the compound concentration (or conditioned media log dilution) at which HBsAg secretion was reduced by 50% compared to the no drug control.
  • the compounds of the present invention were tested for their activity to inhibit HBsAg as described herein.
  • the Examples were tested in the above assay and found to have IC 50 below 25.0 ⁇ M.
  • Particular compounds of formula I were found to have IC 50 below 0.100 ⁇ M. More Particular compounds of formula I were found to have IC 50 below 0.010 ⁇ M.
  • Results of HBsAg assay are given in Table 1.
  • Table 1 Activity data of particular compounds Example No. IC 50 ( ⁇ M) Example No. IC 50 ( ⁇ M) Example No. IC 50 ( ⁇ M) Example No. IC 50 ( ⁇ M) Example No.
  • IC 50 ( ⁇ M) 1 0.064 11 0.17 21 0.006 31 0.004 2 0.01 12 0.005 22 0.021 32 0.11 3 0.003 13 0.006 23 0.018 33 0.035 4 1.16 14 0.002 24 0.01 34 0.024 5 0.8 15 0.002 25 0.003 35 0.022 6 1.93 16 0.009 26 0.004 36 0.003 7 0.009 17 0.018 27 0.003 37 4.42 8 0.094 18 0.097 28 0.01 9 0.083 19 0.005 29 0.064 10 0.01 20 0.037 30 0.32
  • the assay employs real-time qPCR (TaqMan) to directly measure extracellular HBV DNA copy number.
  • HepG2.2.15 cells were plated in 96-well micro titer plates. Only the interior wells were utilized to reduce "edge effects" observed during cell culture, the exterior wells were filled with complete medium to help minimize sample evaporation.
  • the HepG2.2.15 cells were washed and the medium was replaced with complete medium containing various concentrations of a test compound in triplicate. 3TC was used as the positive control, while media alone was added to cells as a negative control (virus control, VC). Three days later, the culture medium was replaced with fresh medium containing the appropriately diluted drug.
  • the cell culture supernatant was collected, treated with pronase and then used in a real-time qPCR/TaqMan assay to determine HBV DNA copy numbers.
  • Antiviral activity was calculated from the reduction in HBV DNA levels (IC 50 ).
  • the compounds of the present invention were tested for their activity to anti HBV DNA production as described herein.
  • the Examples were tested in the above assay and found to have IC 50 below 25.0 ⁇ M.
  • Particular compounds of formula I were found to have IC 50 below 0.10 ⁇ M.
  • Results of HBV DNA assay are given in Table 2.
  • Table 2 Anti HBV DNA production activity in HepG2.2.15 cells Example No. IC 50 ( ⁇ M) 7 ⁇ 0.032 8 ⁇ 0.032 15 ⁇ 0.032

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP16703311.7A 2015-02-11 2016-02-08 Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection Active EP3256471B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015072741 2015-02-11
PCT/EP2016/052585 WO2016128335A1 (en) 2015-02-11 2016-02-08 Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection

Publications (2)

Publication Number Publication Date
EP3256471A1 EP3256471A1 (en) 2017-12-20
EP3256471B1 true EP3256471B1 (en) 2018-12-12

Family

ID=55310820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16703311.7A Active EP3256471B1 (en) 2015-02-11 2016-02-08 Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection

Country Status (6)

Country Link
US (1) US10093671B2 (ja)
EP (1) EP3256471B1 (ja)
JP (1) JP6435054B2 (ja)
CN (1) CN107207505B (ja)
HK (1) HK1244281B (ja)
WO (1) WO2016128335A1 (ja)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
EP3292120B1 (en) 2015-05-04 2019-06-19 H. Hoffnabb-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN107849037B (zh) 2015-07-21 2020-04-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
WO2017017043A1 (en) 2015-07-28 2017-02-02 F. Hoffmann-La Roche Ag Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
LT3785717T (lt) 2015-09-16 2022-04-11 Gilead Sciences, Inc. Coronaviridae infekcijų gydymo būdai
CA3014369A1 (en) 2016-02-19 2017-08-24 Novartis Ag Tetracyclic pyridone compounds as antivirals
US10179792B2 (en) 2016-03-07 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
US10189846B2 (en) 2016-06-10 2019-01-29 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
CN107759585A (zh) * 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
CN110240596B (zh) 2016-07-29 2020-09-11 新波制药有限公司 用于治疗hbv感染的治疗剂
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
DK3526323T3 (da) 2016-10-14 2023-06-26 Prec Biosciences Inc Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet
TW201819380A (zh) * 2016-10-18 2018-06-01 瑞士商諾華公司 作為抗病毒劑之稠合四環吡啶酮化合物
CN110088104B (zh) 2016-11-03 2022-04-12 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物
WO2018083106A1 (en) 2016-11-03 2018-05-11 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN109863145B (zh) 2016-11-03 2022-04-12 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的新的四氢异喹啉和四氢二氮杂萘化合物
AU2017353986B2 (en) 2016-11-07 2021-08-19 Arbutus Biopharma Corporation Substituted pyridinone-containing tricyclic compounds, and methods using same
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
AR110768A1 (es) 2017-01-31 2019-05-02 Gilead Sciences Inc Formas cristalinas de tenofovir alafenamida
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
WO2018154466A1 (en) * 2017-02-21 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Dihydroquinolizinones as antivirals
PT3590942T (pt) * 2017-03-09 2021-07-28 Fujian Cosunter Pharmaceutical Co Ltd Inibidor de antigénio de superfície do vírus da hepatite b
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
SG11201909094VA (en) * 2017-03-31 2019-11-28 Fujifilm Corp 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN108530449B (zh) * 2017-05-22 2021-05-07 河南春风医药科技有限公司 用于治疗或预防乙型肝炎病毒感染的化合物及其制备方法与应用
CN110066278B (zh) 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
CN108976223B (zh) * 2017-06-01 2020-08-07 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
BR112020004112A2 (pt) 2017-08-28 2020-09-24 Enanta Pharmaceuticals, Inc. agentes antiviras da hepatite b
RS64043B1 (sr) * 2017-10-05 2023-04-28 Glaxosmithkline Ip Dev Ltd Hemijska jedinjenja
US10953034B2 (en) 2017-10-16 2021-03-23 Hoffmann-La Roche Inc. Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
EP3694856B1 (en) * 2017-11-22 2023-10-25 Sunshine Lake Pharma Co., Ltd. Fused tricyclic compounds and uses thereof in medicine
GB201720163D0 (en) * 2017-12-04 2018-01-17 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
TW201936192A (zh) 2017-12-06 2019-09-16 美商因那塔製藥公司 B 型肝炎抗病毒試劑
JP2021507906A (ja) * 2017-12-20 2021-02-25 ノバルティス アーゲー 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
SG11202007646UA (en) 2018-02-13 2020-09-29 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CR20210179A (es) 2018-07-03 2022-05-23 Hoffmann La Roche OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058)
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
UY38383A (es) 2018-09-21 2020-04-30 Enanta Pharm Inc Heterociclos funcionalizados como agentes antivirales
CN110950860B (zh) * 2018-09-26 2023-03-31 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
JP2022511378A (ja) 2018-09-30 2022-01-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 縮合四環系化合物および医薬品におけるそれらの使用
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
JP7460644B2 (ja) 2018-10-31 2024-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
AU2020231115A1 (en) 2019-03-07 2021-08-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
CN111848601B (zh) 2019-04-30 2022-06-21 南京海璞医药科技有限公司 一种含稠环的化合物、其应用及含其的药物组合物
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
JP2022548746A (ja) * 2019-09-19 2022-11-21 福建▲広▼生中霖生物科技有限公司 Ｂ型肝炎表面抗原阻害剤の結晶形及びその使用
CA3149557A1 (en) 2019-09-30 2021-04-08 Scott J. Balsitis Hbv vaccines and methods treating hbv
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
AU2021234308C1 (en) 2020-03-12 2024-02-22 Gilead Sciences, Inc. Methods of preparing 1'-cyano nucleosides
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
JP2023526345A (ja) 2020-05-15 2023-06-21 福建▲広▼生中霖生物科技有限公司 Ｂ型肝炎の治療に使用される組み合わせ
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
CN111943946B (zh) * 2020-08-19 2022-07-01 中国医学科学院医药生物技术研究所 含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用
WO2022046631A1 (en) 2020-08-24 2022-03-03 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TW202233204A (zh) 2020-08-27 2022-09-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
US20230000873A1 (en) 2021-05-26 2023-01-05 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
US20230212199A1 (en) 2021-08-18 2023-07-06 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202345786A (zh) 2022-03-02 2023-12-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US20230382940A1 (en) 2022-03-03 2023-11-30 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2023168194A1 (en) 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2023239665A1 (en) 2022-06-06 2023-12-14 Gilead Sciences, Inc. Methods for treatment of viral infections including sars-cov-2
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20240043466A1 (en) 2022-06-30 2024-02-08 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60197684A (ja) * 1984-03-21 1985-10-07 Dainippon Pharmaceut Co Ltd ベンゾ〔ａ〕キノリジン誘導体およびその塩
CN103450184A (zh) * 2012-05-29 2013-12-18 上海壹志医药科技有限公司 斯氏紫堇碱衍生物的盐
SG11201605970QA (en) * 2014-01-30 2016-08-30 Hoffmann La Roche Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
CA2948080A1 (en) * 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US9637485B2 (en) * 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US10093671B2 (en) 2018-10-09
CN107207505A (zh) 2017-09-26
CN107207505B (zh) 2018-12-14
EP3256471A1 (en) 2017-12-20
JP6435054B2 (ja) 2018-12-05
HK1244281B (zh) 2020-02-07
US20170342069A1 (en) 2017-11-30
JP2018505198A (ja) 2018-02-22
WO2016128335A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
EP3256471B1 (en) Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
EP3325477B1 (en) Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
EP3328858B1 (en) Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
EP3143020B1 (en) Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
EP3215504B1 (en) 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
EP3328855B1 (en) Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
EP3535261B1 (en) Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP3180319B1 (en) Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
EP3099685B1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
KR20160097371A (ko) B형 간염 바이러스 감염의 치료 및 예방을 위한 다이하이드로퀴놀리진온

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180622

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1075827

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016008153

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20181212

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190312

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190312

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1075827

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190313

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190412

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190412

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016008153

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190208

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

26N No opposition filed

Effective date: 20190913

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190228

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20160208

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181212

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240123

Year of fee payment: 9

Ref country code: GB

Payment date: 20240123

Year of fee payment: 9

Ref country code: CH

Payment date: 20240301

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240123

Year of fee payment: 9